Loading...
XKRX
004310
Market cap135mUSD
Oct 08, Last price  
7,760.00KRW
1D
-5.02%
1Q
58.85%
Jan 2017
63.58%
Name

Hyundai Pharmaceutical Co Ltd

Chart & performance

D1W1MN
XKRX:004310 chart
P/E
72.32
P/S
0.95
EPS
107.31
Div yield, %
0.39%
Shrs. gr., 5y
-0.92%
Rev. gr., 5y
7.60%
Revenues
191.79b
+9.14%
111,663,468,000120,520,284,000122,879,077,000111,860,453,000113,046,193,000102,253,367,360108,135,474,310107,836,679,060109,829,319,990120,021,835,020130,480,291,100130,790,769,420134,649,736,200132,965,511,610139,802,753,000162,690,046,000180,762,659,000175,735,499,250191,794,999,000
Net income
2.52b
P
9,736,198,0003,475,226,0001,670,588,0002,968,064,000989,545,000-4,849,874,0501,414,880,0501,468,256,1201,593,782,2801,260,887,3601,458,346,750-2,106,347,7901,212,848,4802,187,063,540-3,173,176,000-164,583,0006,121,760,000-574,887,5102,516,256,000
CFO
-123m
L-94.81%
6,202,364,000-1,098,603,000-6,889,088,0002,678,234,0007,847,499,000-2,697,301,9107,951,085,7603,470,131,760-2,848,169,700-2,746,972,140-1,981,203,1203,399,507,8405,713,714,11010,804,339,0005,132,209,00011,623,767,000-4,545,283,000-2,373,256,000-123,285,115
Dividend
Mar 03, 202630 KRW/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Headquartered in Seoul, South Korea, Hyundai Pharmaceutical Co., Ltd. is an international manufacturer and distributor of a diverse portfolio that includes pharmaceutical products, health food beverages, and medical equipment. The company's extensive offerings comprise both prescription (ETC) and over-the-counter (OTC) remedies, addressing a broad spectrum of therapeutic areas. These encompass conditions related to cardiovascular health, infectious diseases, the central nervous system, pain management, respiratory ailments, dermatological issues, digestive and endocrine system disorders, gynecological health, and ophthalmic care. Additionally, their range extends to nutritional supplements, diagnostic reagents, wound healing solutions, and treatments for allergies, arthritis, and anemia, among many others. The company was founded in 1965.

Key people

Han Gu Lee
Chairman · since 2023
Sang Jun Lee
President, Chief Executive Officer, Director · since 2018
Yi Sun Hwang
Vice President · since 2006
Seong Heon Kim
Vice President · since 2020
Chi Yong Kim
Managing Director · since 2021
Ju Hwan Lee
Managing Director · since 2022
Jae Hun Lee
Managing Director · since 2021
Yu Hyeon Park
Managing Director · since 2024
Sin Suk Ryu
Managing Director
Taek Sang Woo
Managing Director · since 2022
Yeong Dong Cha
Assistant Managing Director · since 2023
Jae Pil Gwon
Assistant Managing Director · since 2023
Jun Cheol Ha
Assistant Managing Director · since 2024
Yeong Wuk Jang
Assistant Managing Director · since 2022
Jae Hwon Lee
Assistant Managing Director · since 2024
Seok Ho Lee
Assistant Managing Director · since 2024
Chang Ho Shin
Assistant Managing Director
Yong Hun Choi
Non-Executive Independent Director · since 2024
Byeong Jun Jeon
Non-Executive Independent Director · since 2024
Yeong Gi Kim
Non-Executive Independent Director · since 2023
IPO date
Jun 28, 1978
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑112024‑112023‑112022‑112021‑112020‑112019‑112018‑112017‑112016‑11
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT